Seqens Group, formerly known as PCAS, is a leading global provider of specialty chemicals and pharmaceutical solutions based in France. The company's headquarters is located in Paris, France, and it operates through multiple subsidiaries worldwide, positioning itself as a global player in the industry. Seqens has a long and distinguished history dating back to 1962 when it was founded as Pharmaceutical Chemicals and Synthesis (PCAS).

Over the years, the company has evolved and expanded its portfolio, acquiring other major chemical and pharmaceutical companies. In 2019, PCAS rebranded itself as Seqens Group, representing its vision to create a sustainable and integrated offering of specialty chemicals and pharmaceutical solutions. The company's main products include specialty chemicals, pharmaceutical intermediates, active pharmaceutical ingredients (APIs), custom synthesis, and high-value-added chemical services.

Seqens serves various industries such as pharmaceuticals, cosmetics, electronics, agrochemicals, and performance chemicals. On a global scale, Seqens operates through numerous subsidiaries, joint ventures, and partnerships. It has manufacturing sites and research facilities spread across Europe, North America, and Asia.

Some noteworthy subsidiaries include Chemoxy International Ltd, which specializes in custom manufacturing and advanced intermediates, and Seqens Custom Specialties, which offers custom synthesis and contract manufacturing services. In terms of market position, Seqens is recognized as a leading player in the specialty chemicals and pharmaceutical solutions industry. The company has a strong presence in Europe and the Americas, with a growing focus on the Asian market.

Seqens has achieved several significant milestones and changes in its strategy. The rebranding to Seqens Group signifies its commitment to sustainability, innovation, and customer-centricity. The company has also made strategic acquisitions, such as the purchase of Bristol-Myers Squibb's API manufacturing facility in France, to expand its capabilities and market reach.

As of the latest information available, Seqens continues to innovate and invest in research and development to drive growth and meet the evolving needs of its customers. The company maintains a strong commitment to sustainable practices and aims to become a key player in green chemistry. In conclusion, Seqens Group is a globally recognized provider of specialty chemicals and pharmaceutical solutions.

With its wide range of products and services, strategic partnerships, and commitment to sustainability, the company remains well-positioned in the global market